Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tolterodine + mirabegron
- Development stage
- Unknown
- Lead developer
- 亞東醫院
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy consisting of tolterodine, an antimuscarinic agent, and mirabegron, a beta-3 adrenergic receptor agonist. It is being evaluated by Far Eastern Memorial Hospital in a Phase 4 clinical trial for the treatment of overactive bladder syndrome (OAB) in women. The combination aims to improve efficacy by targeting two different physiological pathways: tolterodine blocks muscarinic receptors to reduce involuntary bladder contractions, while mirabegron activates beta-3 adrenoceptors to promote bladder relaxation during the storage phase. The study specifically investigates the impact of this combination on autonomic function (heart rate variability) and bladder blood perfusion.
- Other names
- mirabegron and tolterodine combination therapytolterodine and mirabegron
02
Targets
CHRM3 (M3)ADRB2 (β2)ADRA1D (α1D)ADRB1 (β1)ADRA1A (α1A)ADRB3 (β3)
Beyond the preview
Go deeper on tolterodine + mirabegron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tolterodine + mirabegron.